Luke Timmerman

Luke Timmerman

Creator
0 followers

Biotech journalist and author; founder of the Timmerman Report, offering deep industry coverage and analysis.

Two Cancer Startups Secure $237M for Antibody Innovations
SocialApr 8, 2026

Two Cancer Startups Secure $237M for Antibody Innovations

A couple cool cancer drug startups profiled this week in TR. Sidewinder Therapeutics with $137M for bispecific ADCs https://t.co/tJcQwI7C4U and Stipple Bio with $100M for novel targets for antibody drugs. https://t.co/rbXkuaRpoe

By Luke Timmerman
CEO Kazimi Explores Computation, Chemistry, Culture in Drug Discovery
SocialApr 7, 2026

CEO Kazimi Explores Computation, Chemistry, Culture in Drug Discovery

Computation, Chemistry & Culture for Drug Discovery: Nimbus Therapeutics CEO Abbas Kazimi is the latest guest on The Long Run. Sponsored by @AlphaSenseInc and Dash Bio. https://t.co/XCysW6El1o

By Luke Timmerman
Nature-Inspired Drug Discovery Discussed on The Long Run
SocialMar 31, 2026

Nature-Inspired Drug Discovery Discussed on The Long Run

Inspired by Mother Nature, Discovering New Drugs. @viswacolluru of @lifeschemistry is the latest guest on The Long Run. Sponsored by @AlphaSenseInc and Dash Bio. https://t.co/F01HMam6Ul

By Luke Timmerman
Europe's Biotech Funding Gap Spurs Urgent Investment Push
SocialMar 18, 2026

Europe's Biotech Funding Gap Spurs Urgent Investment Push

Europe's Biotech Investing Crisis: @OtelloVC Otello Stampacchia of Omega Funds discusses the drive to increase EU biotech investment on The Long Run. Sponsored by @AlphaSenseInc & Dash Bio https://t.co/ORIeN8IDEq

By Luke Timmerman
Alumni Share Timmerman Traverse Experience – Join Now
SocialMar 3, 2026

Alumni Share Timmerman Traverse Experience – Join Now

Join the Timmerman Traverse. WATCH alumni Ted Love, Amy Abernethy, Doug Fambrough and Bonnie Anderson. https://t.co/49ZC5b4mKy

By Luke Timmerman
T‑cell Engagers Offer New Autoimmunity Treatment Opportunity
SocialMar 3, 2026

T‑cell Engagers Offer New Autoimmunity Treatment Opportunity

T-cell engagers for autoimmunity. Listen to Ken Song describe the opportunity as CEO of San Diego-based Candid Therapeutics. Sponsored by @AlphaSenseInc & Dash Bio. https://t.co/Ct2viH00c4

By Luke Timmerman
New Drug Discoveries Target Cancer and Autoimmunity
SocialFeb 20, 2026

New Drug Discoveries Target Cancer and Autoimmunity

Discovering Drugs for Cancer and Autoimmunity. Listen to @Satpathology on The Long Run podcast. Sponsored by @AlphaSenseInc Dash Bio. https://t.co/02keVFdqzj

By Luke Timmerman
Timmerman Traverse Reaches $1M Milestone, Kilimanjaro Countdown
SocialJan 7, 2026

Timmerman Traverse Reaches $1M Milestone, Kilimanjaro Countdown

Timmerman Traverse for Damon Runyon Cancer Research Foundation has hit its $1M goal. One month to go before Kilimanjaro. https://t.co/xb01xFyZoG

By Luke Timmerman